Compare STOK & ASAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | ASAN |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2019 | 2020 |
| Metric | STOK | ASAN |
|---|---|---|
| Price | $29.35 | $6.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | ★ $39.20 | $12.46 |
| AVG Volume (30 Days) | 900.7K | ★ 5.5M |
| Earning Date | 05-08-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.73 | 27.93 |
| EPS | N/A | ★ N/A |
| Revenue | $184,420,000.00 | ★ $790,806,000.00 |
| Revenue This Year | N/A | $10.19 |
| Revenue Next Year | $77.49 | $7.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 404.50 | 9.25 |
| 52 Week Low | $12.25 | $5.38 |
| 52 Week High | $40.22 | $15.71 |
| Indicator | STOK | ASAN |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 43.27 |
| Support Level | $28.22 | $6.45 |
| Resistance Level | $33.51 | $6.88 |
| Average True Range (ATR) | 1.64 | 0.52 |
| MACD | -0.20 | -0.09 |
| Stochastic Oscillator | 28.37 | 22.32 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.